CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $587,866 | -24.1% | 32,623 | -32.4% | 0.27% | -57.4% |
| Q1 2023 | $774,815 | -54.9% | 48,245 | -48.6% | 0.63% | -38.1% |
| Q4 2022 | $1,718,242 | -5.0% | 93,893 | +2.0% | 1.02% | -1.3% |
| Q3 2022 | $1,808,000 | +194.5% | 92,047 | +179.4% | 1.03% | +178.4% |
| Q2 2022 | $614,000 | -36.8% | 32,948 | -25.5% | 0.37% | -39.9% |
| Q1 2022 | $971,000 | -35.5% | 44,226 | -16.5% | 0.62% | -48.5% |
| Q4 2021 | $1,505,000 | +211.6% | 52,982 | +71.8% | 1.20% | +240.3% |
| Q3 2020 | $483,000 | +7.3% | 30,845 | +20.0% | 0.35% | -5.6% |
| Q2 2020 | $450,000 | – | 25,701 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |